Mayo – The Bell Tolled or, It’s the End of the World as We Know It (And I Feel Fine) May 3, 2012 AIPLA Biotechnology Committee Webinar James J. Kelley.

Slides:



Advertisements
Similar presentations
How to Patent Software? It is simply ridiculous that after 40 years of debate, we still do not have an answer to the simple question of whether (or when)
Advertisements

EECS 690 Patents and Software 23 February Patents Must be applied for In order to be patentable, a device or process must be: –New –Useful –Non-Obvious.
Navigating the Post- Prometheus World Technology Transfer Tactics Webinar May 3, 2012 Kevin E. Noonan, Ph.D.
No longer business as usual Patent-eligibility of “business methods” Nicholas Milne Senior Associate Baxter IP.
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
TJSTEL Symposium March 19, 2010 Ahmed J. Davis Fish & Richardson, P.C. The Bilski Tea Leaves: Which Way Will They Go?
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Orlando, Florida | Mayo v. Prometheus by:Jon M. Gibbs Lowndes, Drosdick, Doster, Kantor and Reed PA.
Diagnostics: Patent Eligibility and the Industry Perspective
1.  35 U.S.C. § 101: “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful.
© 2011 Sterne, Kessler, Goldstein, & Fox P.L.L.C. All Rights Reserved. Patenting Biomarkers and Diagnostic Methods Neil P. Shull, Ph.D., J.D. S TERNE,
What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.
LATEST DEVELOPMENTS IN BIOTECH PATENTS Carine van den Brink 18 April 2012.
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
Patents and Threats to Educational Institutions Joshua D. Sarnoff Washington College of Law American University Washington, DC, USA
© 2011 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Patenting Methods of Medical Treatment in the United States AIPPI 2011 Forum/ExCo Peter.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
11 Post-Bilski Case Law Update Remy Yucel Director, Central Reexamination Unit.
1 1 AIPLA Firm Logo American Intellectual Property Law Association CURRENT STATE OF 35 USC 101: “USPTO GUIDELINES ON PRODUCTS OF NATURE, LAWS OF NATURE,
Mayo v. Prometheus Decided March 20, 2012 Roberte Makowski, Ph.D., J.D. Hans Sauer, Ph.D., J.D.
AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College.
More on Section 101 Patent Law Prof. Merges
Bilski: Will It Affect Bioscience Method Claims? Mark T. Skoog, Ph.D. Merchant & Gould MIPLA Biotech/Chemical Law Committee November 2009.
Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts | | fax | wolfgreenfield.com Recent Developments.
Consultant F. Hoffmann La Roche
Drugs which are not patentable
Intellectual Property Boston College Law School March 26, 2008 Software – Patent.
Pop Quiz! What new technology has the United States and Japan engaged in the virtual equivalent of the space race?
1 1 AIPLA Firm Logo American Intellectual Property Law Association Myriad Guidance for Biotechnology and Chemical Practice Joerg-Uwe Szipl Griffin and.
Medical Device Partnership: USPTO Interim Eligibility Guidance Michael Cygan, USPTO June 2, 2015.
Intellectual Property Boston College Law School March 18, 2009 Software – Copyright – Fair Use.
AIPLA Biotech Committee Annual Meeting 2011 Practice Strategies In View of Recent Case Law Developments Panel – James Kelley, Eli Lilly and Company – Ling.
Public Policy Considerations and Patent Eligible Subject Matter Relating to Diagnostic Inventions Disclaimer: Any views expressed here are offered in order.
Judicially Created Diversity in Patent Law Norman Siebrasse Professor of Law University of New Brunswick, Canada.
IAEA International Atomic Energy Agency Interventional Radiology Radiation Sources in medicine diagnostic Radiology Day 7 – Lecture 1(3)
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
© 2011 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is the property of Barnes & Thornburg LLP which may not be reproduced,
Patenting Challenges for Diagnostic Methods: Patent Eligibility; Divided Infringement October 20, 2011 AIPLA Annual Meeting Washington, D.C. James J. Kelley.
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
1 1 AIPLA Firm Logo American Intellectual Property Law Association Politics, Health Care, Subject Matter Eligibility, & Patent Preemption Mercedes K. Meyer,
Chapter 5: Patent Protection for Computer Software & Business Methods.
Intellectual Property: Patent Eligible Subject Matter Prof. Peng
© 2011 Dannemann Siemsen. Todos os direitos reservados. Biotech IP issues in Brazil Gustavo Morais May 2011 Gustavo Morais May 2011.
FLEXIBLE BUDGET Pertemuan 8 dan 9 Matakuliah: > Tahun: >
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
AMP v. US PTO: Section 101 and DNA Sequence Patents Joshua D. Sarnoff DePaul U. College of Law 25 E. Jackson Blvd. Chicago, IL,
MRNA Expression Experiment Measurement Unit Array Probe Gene Sequence n n n Clinical Sample Anatomy Ontology n 1 Patient 1 n Disease n n ProjectPlatform.
#ACIPIV ACI’s 9 th Annual Paragraph IV Disputes Neal K. Dahiya Senior Counsel – Patent Litigation Bristol-Myers Squibb (Princeton, NJ) Limelight v. Akamai:
Pharmaceutical Composition Claims and Enablement Robert J. Hill, Jr. Quality Assurance Specialist Technology Center
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with A Prosecution Perspective on the Protection of Computer Implemented.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
What is Patentable Subject Matter? Dan L. Burk Chancellor’s Professor of Law University of California, Irvine.
The Subject Matter of Patents I Class Notes: April 3, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
A Madness to the Method? The Future of Method Patents After Bilski Brian S. Mudge July 19, 2010.
Surviving Subject Matter in the Post Prometheus/Myriad World Lesley Rapaport LRR Patent Law Denise M. Kettelberger Sunstein Kann Murphy & Timers LLP Carmela.
Korean Intellectual Property Office October 19, 2011 Sunhee Lee, SUGHRUE MION PLLC RECENT CASES IN BIOTECH/PHARM/CHEM & 2011 AMERICA INVENTS ACT.
Jody Blanke, Professor Computer Information Systems and Law 1.
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP AIPLA BIOTECHNOLOGY COMMITTEE WEBINAR Leslie McDonell The contents of.
The Challenge of Biotech Patent Eligibility in the United States:
Homework Assistance Guide
Section 13.7 Linear Correlation and Regression
Getting Patents in the Face of Rejections under Section 101
Law Conservation of Mass and Balanced and Unbalanced Equations
Entropy and Gibbs Energy
Recent USPTO Developments on Subject Matter Eligibility
Protection of Computer-Related Invention in Japan
What Is Patentable Subject Matter. Changing Perspectives in the
Presentation transcript:

Mayo – The Bell Tolled or, It’s the End of the World as We Know It (And I Feel Fine) May 3, 2012 AIPLA Biotechnology Committee Webinar James J. Kelley Senior Director – Assistant General Patent Counsel Eli Lilly and Company Indianapolis, Indiana The contents of this presentation represent the views of the author and do not represent the policies, viewpoints, or business of Lilly or its management.

A method of optimizing therapeutic efficacy for treatment of [condition X]…, comprising: – (a) administering a [particular] drug … to a subject; and – (b) determining the level of [biomarker] in said subject, – wherein the level of [biomarker] less than about 230 … indicates a need to increase the [dose] and – wherein the level of [biomarker] greater than about 400 … indicates a need to decrease the [dose]. Mayo v. Prometheus Conventional

Flook v. Diehr “The claim before us presents a case for patentability that is weaker than the (patent- eligible) claim in Diehr and no stronger than the (unpatentable) claim in Flook.” Mayo, slip op. at 13.

Flook 1. A method for updating the value of at least one alarm limit on at least one process variable involved in a process comprising the catalytic chemical conversion of hydrocarbons wherein said alarm limit has a current value of Bo+K wherein Bo is the current alarm base and K is a predetermined alarm offset which comprises: (1) Determining the present value of said process variable, said present value being defined as PVL; (2) Determining a new alarm base B1, using the following equation: B1=Bo(1-F)+PVL(F) where F is a predetermined number greater than zero and less than 1.0; (3) Determining an updated alarm limit which is defined as B1+GK; and thereafter (4) Adjusting said alarm limit to said updated alarm limit value. “… the formula is the only novel feature of respondent's method. The question is whether the discovery of this feature makes an otherwise conventional method eligible for patent protection.” Flook, 437 U.S. at 588. Conventional

Diehr 1. A method of operating a rubber-molding press for precision molded compounds with the aid of a digital computer, comprising: a)providing said computer with a data base for said press …, b)initiating an interval timer …, c)constantly determining the temperature (Z) of the mold at a location closely adjacent to the mold cavity in the press during molding, d)constantly providing the computer with the temperature (Z), e)repetitively calculating in the computer, at frequent intervals during each cure, the Arrhenius equation for reaction time during the cure, which is ln v = CZ+x, where v is the total required cure time, f)repetitively comparing in the computer at said frequent intervals during the cure each said calculation of the total required cure time calculated with the Arrhenius equation and said elapsed time, and g)opening the press automatically when a said comparison indicates equivalence. 450 U.S. 175, 181, footnote 5. Conventional “Contribution”

Flook v. Diehr v. Mayo Flook (1) (2) (3) Equation (4) Diehr a) b) c) d) e) Equation f) g) Mayo (1) (2) (3) Law of Nature Not Eligible Eligible

Claim Types Diagnostic correlations Biomarkers – Genes, alleles, polymorphisms, proteins – Metabolites – Single biomarkers – Multiple biomarkers General technology “platforms” – machines Kits Reagents – antibodies (for proteins) – probes (for genes) – chemicals Diagnostics in the guise of treatments? MayoMyriad?

E=mc 2 Linear Accelerator Control Room Linear Accelerator OK Al. Niels – My law relates mass and energy. I trust you to use it where relevant. If only I could get a patent claim that recites my law and says “apply the law.” That would be Diehr! No, that would be a Flook. I am now in a Funk. So are a Myriad of patent attorneys. With what does this Natural Phenomenon correlate? Mayo.